BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Minority Interest

Track NewAmsterdam Pharma Company NV's minority interest ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer trimmed avg / median

Loading

NewAmsterdam Pharma Company NV Minority Interest History

Loading

NewAmsterdam Pharma Company NV vs. peers: Minority Interest Comparison

Loading

NewAmsterdam Pharma Company NV Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NewAmsterdam Pharma Company NV (NAMS) FAQ

NewAmsterdam Pharma Company NV (NAMS) currently reports a minority interest of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore NewAmsterdam Pharma Company NV's minority interest history and peer comparisons.

NewAmsterdam Pharma Company NV's minority interest changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NewAmsterdam Pharma Company NV reported $0 in minority interest as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current minority interest of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.